SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is facing volatility following reports that Meta Platforms is planning to commercialize its excess AI compute capacity, sparking investor concerns over potential competition and future supply saturation. Despite this, many in the community view the sell-off as an overreaction, highlighting that long-term capacity agreements remain intact and that the move essentially validates the high value and structural scarcity of AI infrastructure.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is surging after reports that it plans to launch a cloud initiative to monetize excess AI compute capacity, a move that positions the company as a potential rival to existing cloud infrastructure providers. While this development has sparked bullish sentiment regarding Meta's ability to offset massive capital expenditure, it has triggered a sharp sell-off in smaller specialized compute providers as investors weigh the implications of potential supply pressure and new competition in the AI infrastructure space.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing significant volatility as investors debate the impact of reports that Meta is exploring a cloud business to monetize excess AI compute capacity. While some market participants worry this signals potential oversupply and increased competition for neocloud providers, the community remains divided, with many highlighting CoreWeave's durable, long-term contracts and structural demand for AI infrastructure as reasons to view the pullback as a buying opportunity.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is generating significant retail interest as a high-conviction short-squeeze candidate, driven by its exceptionally small public float and high short interest that has captured the attention of traders mirroring the mechanics of past meme-stock rallies. The community is actively debating the stock's turnaround potential and squeeze viability, with many comparing it to other fast-food plays while discussing the impact of management's operational shifts and debt restructuring plans.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as investors focus on its significant short interest and technical potential for a squeeze, while the community debates the company's long-term commercial scaling versus its current reliance on enterprise catalysts.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing heightened attention as investors track its expansion into branded weight-loss drug distribution and upcoming regulatory hearings regarding peptide therapies. The community is actively discussing the stock's institutional backing and its shift toward a recurring, platform-based business model, with many focusing on the balance between growth momentum and potential regulatory volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing intense market volatility as investors weigh the potential for hyperscalers to commercialize excess compute capacity against the long-term structural demand for high-performance AI infrastructure. While the community remains divided over management's capital allocation and communication strategy, bulls point to the company's significant power pipeline and recent NVIDIA Exemplar Cloud status as indicators of fundamental value.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense social media debate as investors weigh the company's recent drone defense partnerships against concerns over shareholder dilution and internal management moves. While some traders are focused on the broader sector rally and potential for a short squeeze, others remain skeptical, warning of ongoing volatility and price pressure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant attention as investors anticipate the upcoming 80th clinical trial event, which many believe will trigger a major buyout or partnership announcement. Community discussions are highly polarized between bulls, who view recent price pullbacks as healthy accumulation zones ahead of transformative data, and bears, who remain skeptical of the clinical trial's potential for statistical success.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning is trending following a massive multiyear agreement with Amazon to supply fiber-optic infrastructure for U.S. data centers, fueling investor enthusiasm for its role as a backbone of the AI buildout. Community discussion remains heavily focused on the company's long-term utility as a critical supplier for hyperscalers, despite short-term price volatility and concerns about rotation within the AI semiconductor and infrastructure sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The New Cancer Moonshot: Innovative Companies Pursuing Game-Changing Therapies

Cancer treatment is undergoing one of the most significant transformations in modern medical history.

PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

Investors Are Watching This High-Stakes Corner of Biotech

The race to improve therapies is heating up as Wall Street hunts for the next winners. NASDAQ:SPRC, NASDAQ:NTHI, NYSE:JNJ, NASDAQ:SMMT, NASDAQ:BNTX

The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers

Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.

Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?

PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.

Wells Fargo & Company Cuts BioNTech (NASDAQ:BNTX) Price Target to $140.00

Wells Fargo & Company lowered their price target on shares of BioNTech from $150.00 to $140.00 and set an "overweight" rating for the company in a report on Wednesday...

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eighteen research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold re...

Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth

Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Why Did BNTX Stock Tumble 17% Pre-Market Today? 

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$2.43	--	--	N/A
Q1 '26	-$2.57	-$2.40	6.57%	BEAT
Q4 '25	-$0.19	-$1.46	-666.92%	MISSED
Q3 '25	-$1.11	-$0.14	87.41%	BEAT
Q2 '25	-$2.64	-$1.85	30.22%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BNTXBioNTech SE - ADR

Upcoming Earnings: Q2 '26

Historical Earnings

Latest BNTX News